ORLANDO - Nutriband Inc. (NASDAQ:NTRB), a developer of transdermal pharmaceutical products, has announced an exclusive partnership with Kindeva Drug Delivery to develop Aversaâ„¢ Fentanyl, a potential ...
Nutriband and Kindeva formalize exclusive product development partnership and long-term commitment based on shared development costs in exchange ...
The expected issuance of this patent further expands Nutriband’s intellectual property protection in the United States for its portfolio of abuse deterrent transdermal products based on its ...
This technology can be incorporated into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. Nutriband’s lead product under ...
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .
This technology can be incorporated into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. Nutriband’s lead product under ...
The AVERSAâ„¢ transdermal abuse deterrent technology is protected by a broad international intellectual property portfolio with patents already issued in 46 countries including the United States ...
The AVERSAâ„¢ transdermal abuse deterrent technology is protected by a broad international intellectual property portfolio with patents already issued in 46 countries including the United States, Europe ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results